P1156: MAGNIFY PHASE 3B STUDY OF LENALIDOMIDE + RITUXIMAB (R2) FOLLOWED BY MAINTENANCE IN RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA: COMPLETE INDUCTION PHASE ANALYSIS
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000847492.88194.df |
| _version_ | 1827335168486014976 |
|---|---|
| author | F. Lansigan D. J. Andorsky M. Coleman A. Yacoub J. M. Melear S. R. Fanning K. S. Kolibaba C. Reynolds G. S. Nowakowski M. Gharibo J. R. Ahn J. Li M. J. Rummel J. P. Sharman |
| author_facet | F. Lansigan D. J. Andorsky M. Coleman A. Yacoub J. M. Melear S. R. Fanning K. S. Kolibaba C. Reynolds G. S. Nowakowski M. Gharibo J. R. Ahn J. Li M. J. Rummel J. P. Sharman |
| author_sort | F. Lansigan |
| collection | DOAJ |
| first_indexed | 2024-03-07T18:10:33Z |
| format | Article |
| id | doaj.art-9752c84003414ff5909ac9baa7e851ba |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T18:10:33Z |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-9752c84003414ff5909ac9baa7e851ba2024-03-02T07:47:21ZengWileyHemaSphere2572-92412022-06-0161043104410.1097/01.HS9.0000847492.88194.df202206003-01043P1156: MAGNIFY PHASE 3B STUDY OF LENALIDOMIDE + RITUXIMAB (R2) FOLLOWED BY MAINTENANCE IN RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA: COMPLETE INDUCTION PHASE ANALYSISF. Lansigan0D. J. Andorsky1M. Coleman2A. Yacoub3J. M. Melear4S. R. Fanning5K. S. Kolibaba6C. Reynolds7G. S. Nowakowski8M. Gharibo9J. R. Ahn10J. Li11M. J. Rummel12J. P. Sharman131 Dartmouth–Hitchcock Medical Center, Lebanon, NH2 Rocky Mountain Cancer Centers, US Oncology Research, Boulder, CO3 Clinical Research Alliance Inc, Weill Cornell Medicine, New York, NY4 University of Kansas Cancer Center, Westwood, KS5 Texas Oncology — Austin, US Oncology Research, Austin, TX6 Prisma Health, US Oncology Research, Greenville, SC7 US Oncology Research, Vancouver, WA8 IHA Hematology Oncology Consultants — Ann Arbor, Ypsilanti, MI9 Mayo Clinic, Rochester, MN10 Bristol Myers Squibb, Princeton, NJ, United States of America10 Bristol Myers Squibb, Princeton, NJ, United States of America10 Bristol Myers Squibb, Princeton, NJ, United States of America11 Justus-Liebig-Universität, Giessen, Germany12 Willamette Valley Cancer Institute and Research Center, US Oncology Research, Eugene, OR, United States of Americahttp://journals.lww.com/10.1097/01.HS9.0000847492.88194.df |
| spellingShingle | F. Lansigan D. J. Andorsky M. Coleman A. Yacoub J. M. Melear S. R. Fanning K. S. Kolibaba C. Reynolds G. S. Nowakowski M. Gharibo J. R. Ahn J. Li M. J. Rummel J. P. Sharman P1156: MAGNIFY PHASE 3B STUDY OF LENALIDOMIDE + RITUXIMAB (R2) FOLLOWED BY MAINTENANCE IN RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA: COMPLETE INDUCTION PHASE ANALYSIS HemaSphere |
| title | P1156: MAGNIFY PHASE 3B STUDY OF LENALIDOMIDE + RITUXIMAB (R2) FOLLOWED BY MAINTENANCE IN RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA: COMPLETE INDUCTION PHASE ANALYSIS |
| title_full | P1156: MAGNIFY PHASE 3B STUDY OF LENALIDOMIDE + RITUXIMAB (R2) FOLLOWED BY MAINTENANCE IN RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA: COMPLETE INDUCTION PHASE ANALYSIS |
| title_fullStr | P1156: MAGNIFY PHASE 3B STUDY OF LENALIDOMIDE + RITUXIMAB (R2) FOLLOWED BY MAINTENANCE IN RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA: COMPLETE INDUCTION PHASE ANALYSIS |
| title_full_unstemmed | P1156: MAGNIFY PHASE 3B STUDY OF LENALIDOMIDE + RITUXIMAB (R2) FOLLOWED BY MAINTENANCE IN RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA: COMPLETE INDUCTION PHASE ANALYSIS |
| title_short | P1156: MAGNIFY PHASE 3B STUDY OF LENALIDOMIDE + RITUXIMAB (R2) FOLLOWED BY MAINTENANCE IN RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA: COMPLETE INDUCTION PHASE ANALYSIS |
| title_sort | p1156 magnify phase 3b study of lenalidomide rituximab r2 followed by maintenance in relapsed refractory indolent non hodgkin lymphoma complete induction phase analysis |
| url | http://journals.lww.com/10.1097/01.HS9.0000847492.88194.df |
| work_keys_str_mv | AT flansigan p1156magnifyphase3bstudyoflenalidomiderituximabr2followedbymaintenanceinrelapsedrefractoryindolentnonhodgkinlymphomacompleteinductionphaseanalysis AT djandorsky p1156magnifyphase3bstudyoflenalidomiderituximabr2followedbymaintenanceinrelapsedrefractoryindolentnonhodgkinlymphomacompleteinductionphaseanalysis AT mcoleman p1156magnifyphase3bstudyoflenalidomiderituximabr2followedbymaintenanceinrelapsedrefractoryindolentnonhodgkinlymphomacompleteinductionphaseanalysis AT ayacoub p1156magnifyphase3bstudyoflenalidomiderituximabr2followedbymaintenanceinrelapsedrefractoryindolentnonhodgkinlymphomacompleteinductionphaseanalysis AT jmmelear p1156magnifyphase3bstudyoflenalidomiderituximabr2followedbymaintenanceinrelapsedrefractoryindolentnonhodgkinlymphomacompleteinductionphaseanalysis AT srfanning p1156magnifyphase3bstudyoflenalidomiderituximabr2followedbymaintenanceinrelapsedrefractoryindolentnonhodgkinlymphomacompleteinductionphaseanalysis AT kskolibaba p1156magnifyphase3bstudyoflenalidomiderituximabr2followedbymaintenanceinrelapsedrefractoryindolentnonhodgkinlymphomacompleteinductionphaseanalysis AT creynolds p1156magnifyphase3bstudyoflenalidomiderituximabr2followedbymaintenanceinrelapsedrefractoryindolentnonhodgkinlymphomacompleteinductionphaseanalysis AT gsnowakowski p1156magnifyphase3bstudyoflenalidomiderituximabr2followedbymaintenanceinrelapsedrefractoryindolentnonhodgkinlymphomacompleteinductionphaseanalysis AT mgharibo p1156magnifyphase3bstudyoflenalidomiderituximabr2followedbymaintenanceinrelapsedrefractoryindolentnonhodgkinlymphomacompleteinductionphaseanalysis AT jrahn p1156magnifyphase3bstudyoflenalidomiderituximabr2followedbymaintenanceinrelapsedrefractoryindolentnonhodgkinlymphomacompleteinductionphaseanalysis AT jli p1156magnifyphase3bstudyoflenalidomiderituximabr2followedbymaintenanceinrelapsedrefractoryindolentnonhodgkinlymphomacompleteinductionphaseanalysis AT mjrummel p1156magnifyphase3bstudyoflenalidomiderituximabr2followedbymaintenanceinrelapsedrefractoryindolentnonhodgkinlymphomacompleteinductionphaseanalysis AT jpsharman p1156magnifyphase3bstudyoflenalidomiderituximabr2followedbymaintenanceinrelapsedrefractoryindolentnonhodgkinlymphomacompleteinductionphaseanalysis |